ARDELYX, INC. Cash and Restricted Cash
ARDELYX, INC. (ARDX) had Cash and Restricted Cash of $97.19 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $97.19M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $31.21M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $68.00M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $42.72M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $97.19M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $31.21M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $68.00M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $42.72M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $90.05M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $30.81M 10-Q · filed 2026-04-30 |
| 2024-12-31 | $64.93M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $47.43M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $41.89M 10-Q · filed 2025-08-04 |
| 2024-03-31 | $36.15M 10-Q · filed 2025-05-01 |
| 2023-12-31 | $21.47M 10-K · filed 2026-02-19 |
| 2023-09-30 | $33.77M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $30.06M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $92.49M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $96.14M 10-K · filed 2026-02-19 |
| 2022-09-30 | $61.63M 10-Q · filed 2023-10-31 |
| 2022-06-30 | $53.41M 10-Q · filed 2023-08-02 |
| 2022-03-31 | $47.08M 10-Q · filed 2023-05-03 |
| 2021-12-31 | $72.43M 10-K · filed 2025-02-20 |
| 2021-09-30 | $75.29M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $86.75M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $84.07M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $91.03M 10-K · filed 2024-02-22 |
| 2020-09-30 | $91.01M 10-Q · filed 2021-11-12 |
| 2020-06-30 | $100.49M 10-Q · filed 2021-08-13 |
| 2020-03-31 | $105.89M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $181.13M 10-K · filed 2023-03-02 |
| 2018-12-31 | $78.77M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |